MedTrace Logo

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

NCT02613208 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab will be administered as per local clinical practice and local labeling.

DRUG

Paclitaxel

Paclitaxel will be administered as per local clinical practice and local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2018-12-03
Completion
2018-12-03

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02613208 on ClinicalTrials.gov